TITLE

OF SPECIAL INTEREST

PUB. DATE
September 2011
SOURCE
American Journal of Health-System Pharmacy;9/15/2011, Vol. 68 Issue 18, p1661
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article offers updates on the effect of fondaparinux prophylaxis on anti-factor xa concentrations in patient with morbid obesity, clinical and economic benefits of aromatase inhibitor therapy in early-stage breast cancer and development and the implementation of an interdisciplinary oncology program in a community hospital.
ACCESSION #
65550362

 

Related Articles

  • New oral anticoagulants for preventing venous thromboembolism. Haut, Elliott R.; Lau, Brandyn D.; Streiff, Michael B. // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;6/30/2012, Vol. 344 Issue 7863, p10 

    No abstract available.

  • Length of treatment for VTE.  // Clinical Cardiology Alert;Feb2012 Pharmacology Watch, p1 

    The article offers information on the study concerning the treatment duration for patients with venous thromboembolism (VTE) wherein additional year of the factor Xa inhibitor apixaban may benefit the patients.

  • Switching drugs improves breast cancer patient survival rates.  // British Journal of Hospital Medicine (17508460);Jan2012, Vol. 73 Issue 1, p8 

    The article discusses the Intergroup Exemestane Study, which revealed that postmenopausal women who switched from tamoxifen to exemestane after 2-3 years in adjuvant treatment of 5 years had higher survival rates; comments from lead study author Professor Judith Bliss are also included.

  • It's a new era in anticoagulant therapy. LOCKWOOD, CHARLES J. // Contemporary OB/GYN;Apr2014, Vol. 59 Issue 4, p8 

    The author discusses the developments in anticoagulant therapy in April 2014. Developments covered include an increase in the occurrence of antepartum venous thrombolic events (VTE) and a decrease in the prevalence of postpartum thrombotic events, the use of D-dimer assessment as a potential...

  • Aspirin and venous thromboembolism. Elliott, William T. // Hospital Medicine Alert;Jul2012 Pharmacology Watch, p2 

    The article discusses findings of a study, according to which, after patients with unprovoked venous thromboembolism (VTE) have finished anticoagulant therapy, use of aspirin reduces the risk of recurrence of VTE, with no apparent increase in risk of major bleeding.

  • Aspirin and venous thromboembolism.  // Clinical Cardiology Alert;7/1/2012, p2 

    The article presents a study which revealed that in patients, with first-ever unprovoked venous thromboembolism (VTE), who have completed an oral anticoagulant treatment, recurrent VTE occurred in 6.6 percent of patients on aspirin and 11.2 percent of patients on placebo.

  • Aspirin and venous thromboembolism. Elliott, William T. // Clinical Oncology Alert;Jul2012 Pharmacology, p2 

    The article presents a study which revealed that in patients, with first-ever unprovoked venous thromboembolism (VTE), who have completed an oral anticoagulant treatment, recurrent VTE occurred in 6.6 percent of patients on aspirin and 11.2 percent of patients on placebo.

  • Optimizing the Prevention and Treatment of Venous Thromboembolism. Bauer, Kenneth A. // Journal of Managed Care Medicine;2011, Vol. 14 Issue 3, p43 

    Although numerous studies have proven the benefits of preventing venous thromboembolism (VTE), patients are still being undertreated. In order to maximize patient outcomes, evidence-based guidelines for preventing and treating VTE should be followed. New anticoagulants are becoming available...

  • Aspirin After Warfarin Prevents Recurrence of VTE. Boyle, Andrew J. // Clinical Cardiology Alert;7/1/2012, p51 

    The author discusses a study by C. Becattini and colleagues, revealing that aspirin reduced the risk of recurrence when given to patients with unprovoked venous thromboembolism (VTE) who had discontinued anticoagulant treatment, with no increase in the risk of major bleeding. He opines that...

  • ONCOLOGY. Ng, Megumi // Journal of Pharmacy Practice & Research;Jun2013, Vol. 43 Issue 2, p156 

    The article presents several abstracts on oncology, including abstracts on the cardiac toxicity of pertuzumab in HER2-positive metastatic breast cancer, the use of exemestane versus anastrozole in early breast cancer and leakage from closed-system transfer devices.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics